Please assess the completion status of the following clinical trial:

Trial Title: Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female ≥ 18 to ≤ 80 years of age~* National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) Framingham risk score of 10% or less~* Fasting LDL-C ≥ 100 mg/dL (2.6 mmol/L) and \<190 mg/dL~* Fasting triglycerides ≤ 400 mg/dL (4.5 mmol/L)~Exclusion Criteria:~* History of coronary heart disease~* New York Heart Association (NYHA) III or IV heart failure~* Uncontrolled cardiac arrhythmia~* Uncontrolled hypertension~* Diabetes mellitus (Type 1 diabetes, poorly controlled type 2 diabetes)~* Uncontrolled hypothyroidism or hyperthyroidism

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Placebo Q2W (Type: PLACEBO_COMPARATOR): Participants received placebo subcutaneous injection once every 2 weeks (Q2W) and placebo tablets once a day for up to 12 weeks.
- Placebo QM (Type: PLACEBO_COMPARATOR): Participants received placebo subcutaneous injection once every month (QM) and placebo tablets once a day for up to 12 weeks.
- Ezetimibe (Q2W) (Type: ACTIVE_COMPARATOR): Participants received placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once a day for up to 12 weeks.
- Ezetimibe (QM) (Type: ACTIVE_COMPARATOR): Participants received placebo subcutaneous injection once a month and 10 mg ezetimibe orally once a day for up to 12 weeks.
- Evolocumab Q2W (Type: EXPERIMENTAL): Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once a day for up to 12 weeks.
- Evolocumab QM (Type: EXPERIMENTAL): Participants received 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once a day for up to 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).